MBX Biosciences appoints Peter Radovich to board of directors

MBX Biosciences, Inc. appointed Peter Radovich as a director effective October 20, 2026, according to an 8-K filed with the Securities and Exchange Commission. The appointment came from the board of directors upon the recommendation of the Nominating and Corporate Governance Committee.¹

The board determined that Radovich is independent under the applicable listing standards of the Nasdaq Stock Market.¹ He has been designated a Class I director to serve until the company's 2028 Annual Meeting of Stockholders, under the company's amended and restated by-laws, continuing thereafter until a successor is elected and qualified or until his earlier death, removal, or resignation.¹ In connection with the appointment, the board set its size at eight directors.¹ The filing does not state what the board's size was prior to this appointment.

On compensation, Radovich will receive, as a non-employee director, an initial award of a non-qualified stock option to purchase 18,200 shares of the company's common stock, to be granted on the October 20, 2026 appointment date.¹ He will also receive cash compensation for board service under the company's Non-Employee Director Compensation Policy as amended in March 2026, which was previously described in the company's Annual Proxy Statement for the period ending December 31, 2025, filed with the SEC on April 22, 2026.¹ The company is also entering into an indemnification agreement with Radovich in the same form used with its other directors.¹

The filing states there are no arrangements or understandings between Radovich and any other persons related to his selection as director, and no transactions requiring disclosure under Item 404(a) of Regulation S-K.¹ The 8-K was signed by Steven L. Hoerter, President and Chief Executive Officer, and dated October 22, 2026.